<DOC>
	<DOCNO>NCT00130312</DOCNO>
	<brief_summary>The purpose study determine whether sulodexide effective slow prevent progression diabetic kidney disease .</brief_summary>
	<brief_title>Effect Sulodexide Overt Diabetic Nephropathy</brief_title>
	<detailed_description>Diabetes common cause end-stage renal disease ( ESRD ) U.S. many develop nation . Diabetic nephropathy represent 44 % new case ESRD U.S . Despite advance clinical care , include improvement glycemic blood pressure control , number new case diabetes related ESRD continue rise . In particular , incidence type 2 diabetes mellitus ( DM2 ) -related case ESRD rapidly increase . From 1993 1997 , 71 % diabetes-related ESRD attributable DM2 ( USRDS 1999 ) . The early sign diabetic kidney disease present microalbuminuria , spill small amount blood protein urine . Microalbuminuria correlate directly subsequent development advance kidney disease . Improved glycemic control blood pressure control use inhibitor renin-angiotensin-aldosterone system reduce level microalbuminuria overt proteinuria . However , despite measure , diabetic nephropathy continue progress , albeit slowly . Sulodexide belong class drug call glycosaminoglycans ( GAG ) . GAG therapy show animal model prevent induce regression albuminuria , morphologic change associate progressive diabetic nephropathy glomerular basement thickening , loss anionic charge density mesangial collagen deposition . Sulodexide approve Europe treat vascular indication . It utilize several small phase II study treat early diabetic nephropathy , induce additional 40-70 % reduction albuminuria subject whose albumin excretion already reduce tight glycemic control plus use inhibitor renin-angiotensin-aldosterone system blood pressure control . The purpose study add body evidence Sulodexide may offer additional benefit prevent ameliorate advanced diabetic nephropathy manifest overt proteinuria reduce GFR . Subjects type 2 diabetes , moderately elevate serum creatinine overt proteinuria treat standardized maximal recommended/tolerated dose irbesartan 300 mg/day losartan 100 mg/day plus additional concomitant non-ARB , non-ACEi antihypertensive drug , 2-3 month establish adequate stable blood pressure control urine protein excretion . After establish baseline serum creatinine urine protein excretion randomize either Sulodexide 200 mg/d match placebo . Subjects see every 3 month monitor safety efficacy parameter 4 year . The primary outcome double baseline serum creatinine ( 50 % loss kidney function ) end stage kidney disease ( ESRD ) .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Glucuronyl glucosamine glycan sulfate</mesh_term>
	<criteria>Diagnosis type 2 diabetes ; Urine protein creatinine ratio ( PCR ) equal great 900 mg/G ( 101.7 mg/mmol ) woman equal great 650 mg/G ( 73.45 mg/mmol ) men ; Serum creatinine woman 1.3 3.0 mg/dL ( 115265 μmol/L ) , inclusive , men 1.5 3.0 mg/dL ( 133265 μmol/L ) , inclusive ; Willing discontinue antihypertensive medication regimen , applicable ; Willing able give inform consent . Type 1 ( insulindependent ; juvenile onset ) diabetes ; Renal disease follow : Patients know nondiabetic renal disease ( nephrosclerosis superimpose diabetic nephropathy acceptable ) , Renal allograft ; Absolute requirement combination therapy angiotensin convert enzyme inhibitor ( ACEI ) angiotensin receptor blocker ( ARB ) ; Patients require ACEI , ACEI/ARB combination ; Cardiovascular disease follow : Unstable angina pectoris within 3 month study entry ; Myocardial infarction , coronary artery bypass graft surgery , percutaneous transluminal coronary angioplasty/stent within 3 month study entry ; Transient ischemic attack within 3 month study entry ; Cerebrovascular accident within 3 month study entry ; New York Heart Association Functional Class III IV ( Note : patient New York Heart Association Functional Class I II require ACEI , consult Clinical Coordinating Center obtain permission patient ACEI rather ARB ) ; Obstructive valvular heart disease hypertrophic cardiomyopathy ; Second third degree atrioventricular block successfully treat pacemaker ; Need chronic ( &gt; 2 week ) immunosuppressive therapy , include corticosteroid ( exclude inhale nasal steroid ) ; New diagnosis cancer recurrent cancer within 5 year screen ( except nonmelanoma skin cancer ) ; Psychiatric disorder interfere patient 's ability comply protocol ; Inability tolerate oral medication history significant malabsorption ; History alcohol drug abuse within 12 month study entry ; Known human immunodeficiency virus disease ; Any medical condition render patient unable unlikely complete study , would interfere optimal participation study produce significant risk patient ; Receipt investigational drug ( include placebo ) within 30 day enrollment ; Evidence hepatic dysfunction include total bilirubin &gt; 2.0 mg/dL ( &gt; 35 micromol/L ) liver transaminase ( aspartate aminotransferase [ AST ] alanine transferase [ ALT ] ) &gt; 3 time upper limit normal ; Anticipate need surgery ; Inability cooperate study personnel history noncompliance medical regimen ; Known allergy intolerance heparinlike compound include heparininduced thrombocytopenia Type II ; Prior exposure sulodexide , either clinical setting participant another clinical study . Untreated urinary tract infection would impact urinary protein value .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Diabetic Nephropathy</keyword>
	<keyword>Proteinuria</keyword>
</DOC>